Amgen's trebananib hits main goal in ovarian cancer trial

06/13/2013 | American City Business Journals

Amgen's experimental drug trebananib, or AMG 386, in combination with paclitaxel, achieved the primary goal of a late-stage study by extending progression-free survival in patients with ovarian cancer. Patients who took trebananib survived 7.2 months without their disease worsening compared with 5.4 months for those in the control group.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX